|Prof. Hermann Lübbert||Co-Founder, Chairman of the Exec. Board & CEO||N/A||N/A||1956|
|Mr. Thomas Schaffer||CFO & Member of the Exec. Board||N/A||N/A||1963|
|Mr. Christoph Dünwald||Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board||N/A||N/A||1968|
|Pamela Keck||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Alexander Richardson||Head of UK Sales Team||N/A||N/A||N/A|
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of mild to moderate acne. The company offers its products primarily in the United States, Europe, and Israel. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Biofrontera AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.